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1. Introduction
 Several antimicrobial resistant bacteria are 
spreading throughout the world. It is difficult 
to treat a patient infected with an immunity to 
antibiotics and to develope a novel antimicrobi-
al agent. Antimicrobial resistant bacteria have 
typically been isolated from hospitals (inpa-
tients, environments and medical staff). In 1969, 
moreover, “the Swann Report” drew attention 
to the potential for antibiotic-resistant bacte-
ria to spread from treated animals to humans 
through consumption. Nevertheless, there was 
little response to this finding until the detection 
of vancomycin-resistant enterococci (VRE), a 
related glycopeptide avoparcin, in animals fed 
the enhanced feed 1). Recently, antimicrobial 
resistant bacteria such as extended-spectrum 
β-lactamase (ESBL) producing Enterobacte-
riaceae and community acquired methicillin 
resistant Staphylococcus aureus (CA-MRSA) 
have been pervaded in healthy humans 2). It 
has been increasingly considered that ESBL 
producing strains are spreading to healthy hu-
mans through the consumption of livestock, 
processed with the use of a broiler like in the 
case of VRE 3).
Although Enterobacteriaceae normally 
exists in the intestinal tracts of humans, it is 
also frequently caused not only various intes-
tinal diseases but also extraintestinal diseases 
such as urinary tract infection, bacteremia, and 
pneumonia. Broad-spectrum oxyminocepha-
losporins, such as cefotaxime, ceftazidime and 
ceftriaxone, have potent activity against En-
terobacteriaceae, which is one of clinical iso-
lates possessing resistance to narrow-spectrum 
β-lactam agents. On the other hand, ESBL is 
produced by Enterobacteriaceae effectively hy-
drolyses the third generation cephalosporins 
but not cephamycins (cefmetazole, cefoxitin) 
or carbapenems (imipenem, meropenem) 4). 
Most ESBLs can be classified into three main 
groups: TEM, SHV, and CTX-M families. The 
number of natural variants found within these 
families has increased; 170, 130, and 100 types 
respectively had been identified by 2010, respec-
tively 5). The CTX-M types of ESBL that can 
efficiently hydrolyze cefotaxime and ceftriaxone 
are spreading in Japan 6). Moreover, interna-
tional attention is brought to the fact that a 
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strain of CTX-M-15 type ESBL producing bacteria 
could hydrolyze ceftazidime and is not susceptible 
to other drugs such as fluoroquinolone 7) 8). Other 
β-lactam agent resistant mechanisms are asso-
ciated with  by upregulation of the chromosom-
al AmpC gene, plasmid mediated AmpC, efflux 
pumps, decreased in the permeability of the 
outer membrane and a mutation of penicillin 
binding protein (PBP). The aim of this research 
is to investigate the characteristics and molec-
ular epidemiology of cefotaxime resistant En-
terobacteriaceae isolated from healthy college 
students.
2. Materials and Methods
2.1 Bacterial Isolates
One hundred and fory-five stool swab sam-
ples were collected from healthy college and 
nursing school students. Stool samples were 
cultured for 18–24 hours in BHI culture media 
(BD, Japan) with 2 mg/mL cefotaxime (Sigma, 
Japan). Growth samples were isolated Mac-
Conkey ager (Eiken Chemical, Japan) including 
2 mg/mL cefotaxime and incubated at 37 ℃ for 
18–24 hours. Colonies were chosen and sub-cul-
tured by the BTB lactose ager (Kokuto-Seiyaku, 
Japan) and identified by Api20E (biomerieux). 
2.2 Antimicrobial Susceptibility Tests
Antimicrobial susceptibility was evaluated 
by ager plate dilution methods with ampicillin 
(Wako, Japan), cefazolin (Sigma, Japan), cef-
metazole (Sigma, Japan), ceftazidime (Sigma, 
Japan), cefotaxime (Sigma, Japan), gentamycin 
(Wako, Japan), amikacin (Wako, Japan), and 
ciprofloxacin (Wako, Japan). Susceptibilities 
to amoxicillin/clavulanate, ceftriaxone, imipen-
em, and meropenem were evaluated using Etest 
(biomerieux). Breakpoints were determined ac-
cording to the recommendations of the CLSI 9). 
Intermediate susceptibility to each antibiotic 
was defined as resistance. An ESBL confirming 
test was performed by double disk synergy test 
(DDST) used with cefotaxime (BD, Japan), ce-
fotaxime/clavulanate (Eiken Chemical, Japan), 
ceftazidime (BD, Japan), and ceftazidime/clavu-
lanate (Eiken Chemical, Japan).
2.3 PCR & DNA Direct Sequence Analysis
2.3.1 β-Lactamase Identification
ESBL and plasmid-mediated AmpC 
β-lactamase (pAmpC) genes were detected 
by PCR amplification of blaCTX-M, blaTEM, and 
blaSHV genes and six main groups (ACCM, CITM, 
DHAM, EBCM, FOXM, MOXM) of pAmpC- 
type genes, as described previously 10) 11) 12). The 
PCR was performed with Takara Ex taq (Taka-
ra Bio, Japan). All PCR amplicons were verified 
by gel electrophoresis on a 1.8 % SeaKem LE 
agarose (Takara Bio, Japan).
2.3.2 Phylogenetic Groups of Escherichia coli 
E. coli isolates were analyzed to determine 
their phylogenetic groups (A, B1, B2, and D) 
using the triplex PCR assay of chuA, yjaA, and 
tspE4.C2, as described previously 13). 
2.3.3 Fluoroquinolone Resistant Mechanisms
The quinolone resistance determining re-
gions (QRDRs) of gyrA and parC genes were 
sequenced, and the correlating amino acids 
were compared with the corresponding regions 
of E. coli strain (GeneBank No. AF052244, 
AB083821). PCR was performed in a final vol-
ume of 25 µL. Each reaction contained 2.0 mM 
MgCl, 0.2 mM dNTPs, 0.4 µM of each primer, 
and 1.0 U of Ex taq. The primers for PCR were 
used as described previously 14) 15). The PCR 
program consisted of an initial denaturation 
step at 95 ℃ for 5 minutes, followed by 30 cycles 
of DNA denaturation at 95 ℃ for 15 seconds, 
annealing at 56 ℃ for 20 seconds, and extension 
at 72 ℃ for 1 minute. After the last cycle, a final 
extension step at 72 ℃ for 5 minutes was add-
ed. PCR products were purified by DNA RNA 






























and Protein Purification Kit  (Macherey- Na-
gel, Germany). After PCR purification, all of 
them were subjected to direct sequencing by the 
dye-terminator method by using the BigDye 
Terminator v3.1 Cycle Sequencing Kit (Ther-
moFisher Science, USA) with the ABI Prism 
3100 Genetic Analyzer (ThermoFisher Science, 
USA). 
3. Results
3.1 Bacterial Isolates and Antimicrobial Sus-
ceptibility Profile
Cefotaxime resistant Enterobacteriaceae was 
isolated from 22 samples (15.2 %) and gathered 
25 strains of the 16 isolates of Escherichia coli, 
3 isolates of Enterobacter cloacae, 2 isolates of 
Citrobacter braakii, 2 isolates of Klebsiella oxy-
toca, 1 isolate of Enterobacter aerogenes, and 1 
isolate of Hafnia alvei. These antibiotic suscep-
tibility are listed in Table 1. The resistant rate 
and MIC parameter is shown in Table 2. Amox-
icillin/clavulanate, ceftriaxone and ciprofloxacin 
were less active with resistance rates of 36, 100, 
and 44 %. Ceftazidime, cefmetazole, and gen-
tamycin had moderate activity, and their resis-
tance rates were 32, 28, and 12 %, respectively. 
All the strains were susceptible to imipenem, 
meropenem, and amikacin. As shawn in Table 
3, moreover 18 strains (16 E. coli and 2 K. oxy-
toca) were positive of ESBL screening DDST. 
3.2 Molecular Characteristic of Antimicrobial 
Resistance Enterobacteriaceae
All of the ESBL-producing E. coli and K. 
oytoca were examined by PCR for the determi-
nation of blaCTX-M genes. Five E. coli and one K. 
oxytoca carried blaTEM combined with blaCTX-M. 
One isolate for which the cefotaxime MIC val-
ue was 2 mg/mL harbored blaSHV. Additionally, 
ACCM was positive in H. alvei. None of the 
other types of AmpC were detected (Table 3). 
Among 18 CTX-M-positive isolates, 4 isolates 
carried CTX-M-1 group ESBL genes, and 13 
isolates carried CTX-M-2 group ESBL genes. 
Isolated E. coli of phylogenetic subgroup D was 
predominant, followed by subgroup B2, A, and 
B1  (Table 4). The qnrA and B of  fluoroquino-
lone binding protein was not detected in any 
strain (data not shown). 
Table 2. Resistant rate and MIC parameter
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4. Discussion
In this study, prevalent rates of the third 
generation cephalosporins resistance Entero-
bacteriaceae in healthy college students were in-
vestigated. The prevalent rate was 15.9 %, much 
higher than that in the previous study reported 
by Luvsansharav UO in Japan 16). One of the 
reasons may be that the fecal samples were col-
lected from the students studying medical and 
nursing techniques in a college. Among the 25 
isolated strains, 16 strains (64.0 %) were E. coli 
producing ESBLs. ESBL is produced by not 
only E. coli by but also K. oxytoca, which was 
susceptible to cefmetazole, ceftazidime, and 
carbapenems. Additionally, SH Choi reported 
that cefepime was susceptible to ESBL produc-
ing strain and could still treat their infections 17). 
Carbapenem is the most commonly used anti-
microbial agent, but it contributes to the initial 
selection of multi-drug resistant organisms.
Ceftazidime resistant isolates were only En-
terobacter sp., Citrobacter sp., and Hafnia sp., 
which were characterized by chromosomally, 
encoded AmpC β-lactamases. In these species, 
upregulation of chromosomal AmpC develop 
resistance to ceftazidime, cefmetazole, and oth-
er third and forth generation cepharosporins. 
Pattarachai K. found that 17 % of non-Esch-
erichia and non-Klebsiella Enterobacteriaceae 
had harboring pAmpC genes and that almost 
all isolates had a coexistence of ESBL genes 
in tertiary care university hospital patients in 
Thailand 18). This study suggested that pAmpC 
harboring Enterobacteriaceae did not emerge in 
healthy adults yet. On the other hand, Amber 
class C (ACC) β- lactamase which H. alvei has 
on its chromosome was detected by AmpC mul-
tiplex PCR. David N reported that the trans-
fer of the plasmid by ACC β-lactamase gene 
of H. alvei and the receipt of plasmids by K. 
pneumoniae occurred during the outbreak in 
their hospital 19). Therefore, the colonization 
Table 3. Characteristic of β-lactamase
Table 4. Relationship between CTX-M types and phylogenetic group of E. coli
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of AmpC overproducing strains is a risk factor 
for spreading plasmid to other species when the 
host initial flora is affected by antimicrobial se-
lection pressure. 
The most prevalent ESBL type is the 
CTX-M-2 group at cefotaxime resistant 
strains in healthy adults. The CTX-M types 
are categorized into four groups; CTX-M-1, 
CTX-M-2, CTX-M-8, and CTX-M-9 groups. 
The CTX-M-2 group ESBLs are dominant in 
hospital patients in Japan 20). In a current study, 
CTX-M-15 type, which belongs to CTX-M-1 
group of ESBL producing E. coli B2-O25:H4-
ST131, developed a resistance to another cef-
tazidime and was found to be emerging in Euro-
pean countries 8). Furthermore, a current study 
suggested that the CTX-M-15 harboring E. coli 
B2-O25:H4-ST131 strain emerge in Japan 7) and 
that the strain could have multiple reservoirs 
from which they spread to different blaCTX-M 
types 21). Nevertheless, this potential strain was 
not isolated in this study because of the suscep-
tibility of CTX-M type producing strains to 
ceftazidime. These strains are resistance to flu-
oroquinolones, aminoglycosides, and other an-
tibiotics. JANIS, a medical surveillance system 
in Japan, reported a drastic increase of fluoro-
quinolone resistance E. coli as the result of iso-
lation at medical facilities. However, this study 
suggests that fluoroquinolone resistant Entero-
baceriaceae is found in ESBL producing strains 
in healthy adults, and this finding may be due 
to previous abuse of antibiotics. The high rates 
of resistance to fluoroquinolone is probably 
caused by chromosome-mediated resistance 
such as point mutations in the gyrase and to-
poisomerase IV genes (Table 5). Quinolones are 
frequently used to treat infections among out-
patients in many countries including Japan. But 
there is concern that these drugs will not be ef-
fective and will apply selection pressure to these 
isolates. Continuous surveillance of antibiotic 
resistance is essential to detect the emergence 
and spread of broad-spectrum β-lactamase 
producing strains in Enterobacteriaceae.
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